Long-term effects of cardiac resynchronization therapy on electrical remodeling in heart failure-A prospective study

2017 ◽  
Vol 40 (11) ◽  
pp. 1279-1285
Author(s):  
Bharatraj Banavalikar ◽  
Anees Thajudeen ◽  
Narayanan Namboodiri ◽  
Krishna Kumar Mohanan Nair ◽  
Abhilash Srivilasam Pushpangadhan ◽  
...  
2011 ◽  
Vol 34 (11) ◽  
pp. 1553-1560 ◽  
Author(s):  
GEORGE THEODORAKIS ◽  
ATHANASIOS KATSIKIS ◽  
EFTHIMIOS LIVANIS ◽  
ANNA KOSTOPOULOU ◽  
STAMATIS ADAMOPOULOS ◽  
...  

2010 ◽  
Vol 2 (1) ◽  
pp. 26
Author(s):  
Isabella Kardasz ◽  
Paola Bendinelli ◽  
Gabriele Borelli ◽  
Maria Luisa De Perna ◽  
Giulio Zucchelli ◽  
...  

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Frank McGrew ◽  
John Boehmer ◽  
Alan Bank ◽  
Elizabeth Galle ◽  
Patrick Yong ◽  
...  

Cardiac resynchronization therapy (CRT) is typically delivered in addition to background heart failure medications that include beta blockers (BB). Since CRT devices also provide rate support, it was hypothesized that CRT may influence BB use post-implant. We sought to compare BB use in the treatment arms of the COMPANION study, which randomized patients (pts) to optimal pharmacological therapy (OPT) alone or in combination with CRT with or without a defibrillator. The database was analyzed retrospectively for a 12-month period post-randomization. BB dosages were evaluated at the 12-month visit with the last follow-up (FU) visit used for those without 12 month FU data. Pts with no FU data were excluded. Dosages are expressed in carvedilol equivalents. The median dose between the two treatment arms were compared as well as up/down titration rates. Of 1520 pts randomized, 1376 (91%) were followed for at least three months and 689 (50%) were followed for at least 12 months. The median dose was 25 mg/day for both groups at baseline (p=0.93) and again at 12 months (p=0.53). BB use between arms is characterized in the tables below: In this retrospective analysis of the COMPANION trial, there was no significant association between treatment arm and BB drug use. Up/down-titration rates and median dosages were virtually identical between the two arms. COMPANION did not require investigators to increase BB dosage; accordingly, a prospective study would be needed to definitively determine if BB dosage can be titrated more aggressively with CRT.


2018 ◽  
Vol 71 (11) ◽  
pp. A440
Author(s):  
Valentina Kutyifa ◽  
Blanca Quesada ◽  
Helmut Klein ◽  
Yitschak Biton ◽  
Scott McNitt ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Zhinian Guo ◽  
Xiaoyan Liu ◽  
Chuan Liu ◽  
Jie Yang ◽  
Xiaofeng Cheng ◽  
...  

Background. Response to cardiac resynchronization therapy (CRT) varies significantly among patients. This study aimed to identify baseline characteristics that could predict super-response to CRT and to evaluate the long-term prognosis in super-responders. Methods. We retrospectively reviewed the data of 73 consecutive patients who received CRT. Patients were considered as super-responders after 6-month follow-up when NYHA class reduction to I or II combined with left ventricular ejection fraction (LVEF) ≥ 50% was observed. Patients were divided into super-responders group and non-super-responders group. All-cause mortality or hospitalization for heart failure (HF) was referred to the combined end point. Results. 17 (23.3%) patients were super-responders. HF duration, left atrial dimension (LAD), and left bundle branch block (LBBB) were independent predictors of super-response to CRT. The combination of HF duration and LAD could provide more robust prediction of super-response than standalone HF duration (0.899 versus 0.789, Z = 2.207, P = 0.027) or standalone LAD (0.899 versus 0.775, Z = 2.487, P = 0.013). super-responders had excellent LV reverse remodeling. The cumulative incidences of combined end point were significantly lower in the super-responders group, LAD ≤ 42mm group, and combination of HF duration ≤ 48 months and LAD ≤ 42mm group. LBBB remained associated with a lowered risk of the combined end point (HR: 0.19, 95% CI: 0.07-0.57, P = 0.003), whereas LAD was associated with a raised risk of the combined end point (HR: 1.09, 95% CI: 1.02-1.17, P = 0.014). Conclusions. HF duration, LAD, and LBBB independently predicted super-response. The combination of HF duration and LAD makes more robust prediction of CRT super-response. Super-responders had excellent LV reverse remodeling and decreased the incidences of the combined end point. LBBB and LAD were independently associated with the combined end point.


Sign in / Sign up

Export Citation Format

Share Document